Compare iShares MSCI Australia ETF (EWA) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs GSK plc — how do they compare? iShares MSCI Australia ETF trades at $28.5 (market cap $1.17B), while GSK plc trades at $46.47 (market cap $91.88B). The key difference: GSK plc is far larger — about 78.5× iShares MSCI Australia ETF's market cap, and GSK plc pays a 3.9% dividend while iShares MSCI Australia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 63 Days and GSK plc for 93 Days on average.
| EWA | GSK | |
|---|---|---|
Market Cap | $1.17B | $91.88B |
Volume | 2,121,231 | 7,730,529 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $61.18 |
52-Week Low | $24.95 | $43.24 |
Typical Hold Time | 63 Days | 93 Days |
Enterprise Value | — | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Australia ETF (EWA) trades at $28.465, up 0.83% today, but technical indicators signal a bearish trend with all moving averages in sell territory. The ETF, which tracks Australian equities, faces headwinds from domestic market volatility and inflation concerns, as Australian shares recently hit a three-month low. Key support and resistance cluster tightly around $28, indicating a critical price zone. Financial ratios are unavailable in the provided data, limiting fundamental assessment.
Outlook remains cautious due to technical weakness and macroeconomic pressures, though some analysts see upside potential from commodity exposure. Risks include persistent inflation, tight monetary policy, and global economic shifts. Investors should weigh the bearish technicals against Australia's resource-driven economic prospects.
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
